about
Role of the gastroenterologist in managing obesityGemcitabine-based chemotherapy for advanced biliary tract carcinomasCirculating MicroRNAs as Biomarkers in Biliary Tract CancersHepatolithiasis and intrahepatic cholangiocarcinoma: A review.Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapiesCancer review: CholangiocarcinomaBiliary strictures: diagnostic considerations and approach.Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studiesCholangiocarcinomaTranscatheter embolization therapy in liver cancer: an update of clinical evidencesParasite Infection, Carcinogenesis and Human MalignancyCancer and liver cirrhosis: implications on prognosis and managementMolecular profiling of biliary tract cancer: a target rich diseaseCholangiocarcinoma: Current Knowledge and New DevelopmentsCurrent Status on Cholangiocarcinoma and Gallbladder CancerClassification, diagnosis, and management of cholangiocarcinomaThe role of the hepatitis viruses in cholangiocarcinomaTargeted therapy in biliary tract cancers-current limitations and potentials in the future.Global epidemiology and burden of HCV infection and HCV-related disease.Liver masses: a clinical, radiologic, and pathologic perspective.Risk of hepatobiliary cancer after solid organ transplant in the United States.Pancreatic recurrence of intrahepatic cholangiocarcinoma: Case report and review of the literature.Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma.Chronic inflammation and cytokines in the tumor microenvironment.Influence of marital status on the survival of adults with extrahepatic/intrahepatic cholangiocarcinoma.Serum albumin predicts survival in patients with hilar cholangiocarcinomaUpdate on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma.Methylated Bone Morphogenetic Protein 3 (BMP3) Gene: Evaluation of Tumor Suppressor Function and Biomarker Potential in Biliary Cancer.Sociodemographic trends in the incidence of pancreatic and biliary tract cancer in UK primary care.Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma.A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancerPathogenesis, diagnosis, and management of cholangiocarcinomaHilar cholangiocarcinoma: diagnosis, treatment options, and management.CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.Over-expression of nerve growth factor-β in human cholangiocarcinoma QBC939 cells promote tumor progression.Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study.MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).Cholangiocarcinoma: molecular pathways and therapeutic opportunities
P2860
Q22241486-68EE1E28-294C-47FA-8C35-DBE109BB05F1Q24187573-191A5F6C-AC66-4182-A501-DD05E8642CF0Q26746000-6B3E78EF-AD6E-46C1-86ED-17A68637D37BQ26771199-FB682892-4DFB-43DF-801A-B38E5D75763BQ26852049-F977E71E-A305-4BB6-8148-299AF89FB7B6Q26865200-BEBA7E88-0BD5-41CC-9511-D07E0F656688Q26998582-AC49F1E0-CB75-443E-9560-0A9D230EB27DQ26998595-6D504C0F-B883-4957-977E-81D3C70E47A1Q27001694-ABAFB0BF-ECD6-4BA2-AF92-13420A7853C9Q27003849-2D79ECFB-6CFA-4143-AA11-934968D849A5Q28067519-1D447B7B-3E5B-43B3-B49D-16CB73864E06Q28068579-4E3C93C8-E43D-4AAB-8C60-CB8181C03A9AQ28072275-66A1F80D-3476-43FF-B6B5-1FB27E891D3BQ28076098-927E4637-EA32-431F-8543-368BFF165526Q28077797-45E99415-B235-4C62-AD01-71AA5E442566Q28275153-C0C2C8EE-4FA1-474F-A8D7-AA248BF72AEAQ28288613-CCC0481E-7C9B-42FD-82B8-5DA6CB163989Q30234532-6DB4EDC7-B734-4B85-9DEF-01E784638E30Q30240220-0A4706F0-8F65-424C-B659-CE771EAACB0AQ30403670-01234355-3603-4FE7-8731-3A988C8AB936Q30581052-192F567C-4021-4D59-9F36-AF7FAB0E55C5Q33580993-7B161AD6-A015-4865-857D-240750BF040AQ33605089-FD981C98-1CA9-422A-B1DC-E92F34B65F14Q33678275-7FCE3984-4D37-4BF4-AE47-E9F6D951D269Q33709965-989AE213-E80E-49DB-840E-E5A928B9131EQ33726891-8E8E3C42-2ECA-4735-9352-65A17B67D66AQ33844564-062D3841-0123-4FF5-9535-0D2DAA609A90Q33955013-E80B3A55-3EBC-4423-92CE-05E4496284C9Q34277315-BFB30A60-75C0-4D30-840D-3D91B98F5456Q34464452-FACE7D5A-7603-45A3-8E8C-FFDDE92E82DFQ34573243-A1DB71C7-08D0-4361-8A42-D306BD461331Q34656747-DED0DFB8-D2D2-4590-A0F1-3B43E1E6B1F0Q34661001-E9DCE133-B350-4974-9BC0-B17A7F517ED2Q34681076-F10678B0-CCAF-4F22-A7F5-725E251D9F12Q34700856-8BFE2115-D8EA-41E9-A6EA-743182C86251Q34764681-B576D25A-45A0-4FB2-8802-C5A4ADEF5845Q34874988-0021B809-4A02-449F-9B9B-8724DA8CBA36Q34895116-59A59F3B-7880-463B-A279-9EF5AFECD3A9Q34911078-3626C23F-9681-4804-B072-43ECB0CD7763Q34959174-B65534CC-084C-4A2B-9786-15659707CC36
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Risk factors for cholangiocarcinoma
@ast
Risk factors for cholangiocarcinoma
@en
type
label
Risk factors for cholangiocarcinoma
@ast
Risk factors for cholangiocarcinoma
@en
prefLabel
Risk factors for cholangiocarcinoma
@ast
Risk factors for cholangiocarcinoma
@en
P2860
P356
P1433
P1476
Risk factors for cholangiocarcinoma
@en
P2093
Gia L Tyson
Hashem B El-Serag
P2860
P304
P356
10.1002/HEP.24351
P407
P577
2011-07-01T00:00:00Z